Faster Production Of Panbela's Pancreatic Cancer Drug

Turning a complex, low-yield synthesis into a streamlined and scalable process can make a real difference between development delays and meaningful clinical progress. In the case of a pancreatic cancer therapy, thoughtful route redesign delivered major improvements in efficiency, chiral purity, and overall manufacturability.

The revised approach introduced alternative starting materials, redesigned key reaction steps, and removed unnecessary transformations to simplify the overall process. At the same time, enhanced analytical methods enabled accurate control and monitoring of chiral purity, ensuring strong alignment with regulatory expectations.

By eliminating chromatography and incorporating more cost-efficient reagents, the process became faster, more robust, and significantly easier to scale. The result is a GMP-ready manufacturing route that improves both quality and operational efficiency, while supporting the therapy’s continued progression toward clinical and commercial milestones.

Explore how strategic process redesign can create a measurable impact across development and manufacturing.